Cargando…

FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related illness worldwide and one of the most common malignancies. Therefore, colorectal cancer research and cases have gained increasing attention. Oxaliplatin (OXA) is currently used in first-line chemotherapy to treat stage III and sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Hsi-Hsien, Kuo, Wei-Wen, Shih, Hui-Nung, Cheng, Sue-Fei, Yang, Ching-Kuo, Chen, Ming-Cheng, Tu, Chuan-Chou, Viswanadha, Vijaya Padma, Liao, Po-Hsiang, Huang, Chih-Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827018/
https://www.ncbi.nlm.nih.gov/pubmed/31623173
http://dx.doi.org/10.3390/cancers11101576
_version_ 1783465229867286528
author Hsu, Hsi-Hsien
Kuo, Wei-Wen
Shih, Hui-Nung
Cheng, Sue-Fei
Yang, Ching-Kuo
Chen, Ming-Cheng
Tu, Chuan-Chou
Viswanadha, Vijaya Padma
Liao, Po-Hsiang
Huang, Chih-Yang
author_facet Hsu, Hsi-Hsien
Kuo, Wei-Wen
Shih, Hui-Nung
Cheng, Sue-Fei
Yang, Ching-Kuo
Chen, Ming-Cheng
Tu, Chuan-Chou
Viswanadha, Vijaya Padma
Liao, Po-Hsiang
Huang, Chih-Yang
author_sort Hsu, Hsi-Hsien
collection PubMed
description Colorectal cancer (CRC) is the second leading cause of cancer-related illness worldwide and one of the most common malignancies. Therefore, colorectal cancer research and cases have gained increasing attention. Oxaliplatin (OXA) is currently used in first-line chemotherapy to treat stage III and stage IV metastatic CRC. However, patients undergoing chemotherapy often develop resistance to chemo drugs being used. Evidence has confirmed that microRNAs regulate downstream genes in cancer biology and thereby have roles related to tumor growth, proliferation, invasion, angiogenesis, and multi-drug resistance. The aim of our study is to establish whether miR-31-5p is an oncogene in human colorectal cancers that are resistant to OXA and further confirm its malignant phenotype-associated target molecule. From the results of miRNA microarray assay, we establish that miR-31-5p expression was upregulated in oxaliplatin-resistant (OR)-LoVo cells compared with parental LoVo cells. Moreover, through in vitro and in vivo experiments, we demonstrate that miR-31-5p and large tumor suppressor kinase 2 (LATS2) were inversely related and that miR-31-5p and Forkhead box C1 (FOXC1) were positively correlated in the same LoVo or OR-LoVo cells. Importantly, we reveal a novel drug-resistance mechanism in which the transcription factor FOXC1 binds to the miR-31 promoter to increase the expression of miR31-5p and regulate LATS2 expression, resulting in cancer cell resistance to OXA. These results suggest that miR-31-5p may be a novel biomarker involved in drug resistance progression in CRC patients. Moreover, the FOXC1/miR31-5p/LATS2 drug-resistance mechanism provides new treatment strategies for CRC in clinical trials.
format Online
Article
Text
id pubmed-6827018
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68270182019-11-18 FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer Hsu, Hsi-Hsien Kuo, Wei-Wen Shih, Hui-Nung Cheng, Sue-Fei Yang, Ching-Kuo Chen, Ming-Cheng Tu, Chuan-Chou Viswanadha, Vijaya Padma Liao, Po-Hsiang Huang, Chih-Yang Cancers (Basel) Article Colorectal cancer (CRC) is the second leading cause of cancer-related illness worldwide and one of the most common malignancies. Therefore, colorectal cancer research and cases have gained increasing attention. Oxaliplatin (OXA) is currently used in first-line chemotherapy to treat stage III and stage IV metastatic CRC. However, patients undergoing chemotherapy often develop resistance to chemo drugs being used. Evidence has confirmed that microRNAs regulate downstream genes in cancer biology and thereby have roles related to tumor growth, proliferation, invasion, angiogenesis, and multi-drug resistance. The aim of our study is to establish whether miR-31-5p is an oncogene in human colorectal cancers that are resistant to OXA and further confirm its malignant phenotype-associated target molecule. From the results of miRNA microarray assay, we establish that miR-31-5p expression was upregulated in oxaliplatin-resistant (OR)-LoVo cells compared with parental LoVo cells. Moreover, through in vitro and in vivo experiments, we demonstrate that miR-31-5p and large tumor suppressor kinase 2 (LATS2) were inversely related and that miR-31-5p and Forkhead box C1 (FOXC1) were positively correlated in the same LoVo or OR-LoVo cells. Importantly, we reveal a novel drug-resistance mechanism in which the transcription factor FOXC1 binds to the miR-31 promoter to increase the expression of miR31-5p and regulate LATS2 expression, resulting in cancer cell resistance to OXA. These results suggest that miR-31-5p may be a novel biomarker involved in drug resistance progression in CRC patients. Moreover, the FOXC1/miR31-5p/LATS2 drug-resistance mechanism provides new treatment strategies for CRC in clinical trials. MDPI 2019-10-16 /pmc/articles/PMC6827018/ /pubmed/31623173 http://dx.doi.org/10.3390/cancers11101576 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hsu, Hsi-Hsien
Kuo, Wei-Wen
Shih, Hui-Nung
Cheng, Sue-Fei
Yang, Ching-Kuo
Chen, Ming-Cheng
Tu, Chuan-Chou
Viswanadha, Vijaya Padma
Liao, Po-Hsiang
Huang, Chih-Yang
FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer
title FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer
title_full FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer
title_fullStr FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer
title_full_unstemmed FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer
title_short FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer
title_sort foxc1 regulation of mir-31-5p confers oxaliplatin resistance by targeting lats2 in colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827018/
https://www.ncbi.nlm.nih.gov/pubmed/31623173
http://dx.doi.org/10.3390/cancers11101576
work_keys_str_mv AT hsuhsihsien foxc1regulationofmir315pconfersoxaliplatinresistancebytargetinglats2incolorectalcancer
AT kuoweiwen foxc1regulationofmir315pconfersoxaliplatinresistancebytargetinglats2incolorectalcancer
AT shihhuinung foxc1regulationofmir315pconfersoxaliplatinresistancebytargetinglats2incolorectalcancer
AT chengsuefei foxc1regulationofmir315pconfersoxaliplatinresistancebytargetinglats2incolorectalcancer
AT yangchingkuo foxc1regulationofmir315pconfersoxaliplatinresistancebytargetinglats2incolorectalcancer
AT chenmingcheng foxc1regulationofmir315pconfersoxaliplatinresistancebytargetinglats2incolorectalcancer
AT tuchuanchou foxc1regulationofmir315pconfersoxaliplatinresistancebytargetinglats2incolorectalcancer
AT viswanadhavijayapadma foxc1regulationofmir315pconfersoxaliplatinresistancebytargetinglats2incolorectalcancer
AT liaopohsiang foxc1regulationofmir315pconfersoxaliplatinresistancebytargetinglats2incolorectalcancer
AT huangchihyang foxc1regulationofmir315pconfersoxaliplatinresistancebytargetinglats2incolorectalcancer